Soluble β2-μ-associated and β2-μ-free HLA class I heavy chain serum levels in interferon-α nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment

Francesco Puppo, Francesco Torre, Paola Contini, Massimo Ghio, Sabrina Brenci, Renata Brizzolara, Nicoletta Sinelli, Nadia Campo, Francesco Indiveri, Antonino Picciotto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The serum levels of soluble β2-μ-associated and β2-μ-free HLA class I heavy chains were determined in 28 interferon-α nonresponder chronic hepatitis C patients retreated with interferon-α plus ribavirin and in 70 healthy subjects. The baseline levels of β2-μ-associated and β2-μ-free HLA class I heavy chains were significantly higher in patients than in healthy controls (P = 0.001). The levels of β2-μ-associated HLA class I heavy chains significantly increased in responder patients with respect to nonresponders at the third month of treatment (P = 0.03). At the sixth month of treatment and after 6 months of follow up the levels of β2-μ-associated HLA class I heavy chains decreased in responder patients and increased in nonresponders. The levels of β2-μ-free HLA class I heavy chains showed only minor changes during and after treatment. We suggest that the determination of hepatitis C virus RNA levels combined with soluble β2-μ-associated HLA class I heavy chains, as a marker of immune activation, could identify interferon-α non responder chronic hepatitis C patients most likely to respond to a retreatment with interferon-α plus ribavirin.

Original languageEnglish
Pages (from-to)486-489
Number of pages4
JournalJournal of Clinical Immunology
Volume20
Issue number6
DOIs
Publication statusPublished - 2000

Fingerprint

Retreatment
Chronic Hepatitis C
Interferons
Antiviral Agents
Biomarkers
Serum
Ribavirin
Hepacivirus
Healthy Volunteers
Therapeutics
RNA

Keywords

  • Chronic hepatitis C
  • Hepatitis C virus RNA
  • Interferon-α
  • Ribavirin
  • Soluble HLA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Soluble β2-μ-associated and β2-μ-free HLA class I heavy chain serum levels in interferon-α nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. / Puppo, Francesco; Torre, Francesco; Contini, Paola; Ghio, Massimo; Brenci, Sabrina; Brizzolara, Renata; Sinelli, Nicoletta; Campo, Nadia; Indiveri, Francesco; Picciotto, Antonino.

In: Journal of Clinical Immunology, Vol. 20, No. 6, 2000, p. 486-489.

Research output: Contribution to journalArticle

Puppo, Francesco ; Torre, Francesco ; Contini, Paola ; Ghio, Massimo ; Brenci, Sabrina ; Brizzolara, Renata ; Sinelli, Nicoletta ; Campo, Nadia ; Indiveri, Francesco ; Picciotto, Antonino. / Soluble β2-μ-associated and β2-μ-free HLA class I heavy chain serum levels in interferon-α nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. In: Journal of Clinical Immunology. 2000 ; Vol. 20, No. 6. pp. 486-489.
@article{bdf853116b674fd5b3c994d841135073,
title = "Soluble β2-μ-associated and β2-μ-free HLA class I heavy chain serum levels in interferon-α nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment",
abstract = "The serum levels of soluble β2-μ-associated and β2-μ-free HLA class I heavy chains were determined in 28 interferon-α nonresponder chronic hepatitis C patients retreated with interferon-α plus ribavirin and in 70 healthy subjects. The baseline levels of β2-μ-associated and β2-μ-free HLA class I heavy chains were significantly higher in patients than in healthy controls (P = 0.001). The levels of β2-μ-associated HLA class I heavy chains significantly increased in responder patients with respect to nonresponders at the third month of treatment (P = 0.03). At the sixth month of treatment and after 6 months of follow up the levels of β2-μ-associated HLA class I heavy chains decreased in responder patients and increased in nonresponders. The levels of β2-μ-free HLA class I heavy chains showed only minor changes during and after treatment. We suggest that the determination of hepatitis C virus RNA levels combined with soluble β2-μ-associated HLA class I heavy chains, as a marker of immune activation, could identify interferon-α non responder chronic hepatitis C patients most likely to respond to a retreatment with interferon-α plus ribavirin.",
keywords = "Chronic hepatitis C, Hepatitis C virus RNA, Interferon-α, Ribavirin, Soluble HLA",
author = "Francesco Puppo and Francesco Torre and Paola Contini and Massimo Ghio and Sabrina Brenci and Renata Brizzolara and Nicoletta Sinelli and Nadia Campo and Francesco Indiveri and Antonino Picciotto",
year = "2000",
doi = "10.1023/A:1026468001834",
language = "English",
volume = "20",
pages = "486--489",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Soluble β2-μ-associated and β2-μ-free HLA class I heavy chain serum levels in interferon-α nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment

AU - Puppo, Francesco

AU - Torre, Francesco

AU - Contini, Paola

AU - Ghio, Massimo

AU - Brenci, Sabrina

AU - Brizzolara, Renata

AU - Sinelli, Nicoletta

AU - Campo, Nadia

AU - Indiveri, Francesco

AU - Picciotto, Antonino

PY - 2000

Y1 - 2000

N2 - The serum levels of soluble β2-μ-associated and β2-μ-free HLA class I heavy chains were determined in 28 interferon-α nonresponder chronic hepatitis C patients retreated with interferon-α plus ribavirin and in 70 healthy subjects. The baseline levels of β2-μ-associated and β2-μ-free HLA class I heavy chains were significantly higher in patients than in healthy controls (P = 0.001). The levels of β2-μ-associated HLA class I heavy chains significantly increased in responder patients with respect to nonresponders at the third month of treatment (P = 0.03). At the sixth month of treatment and after 6 months of follow up the levels of β2-μ-associated HLA class I heavy chains decreased in responder patients and increased in nonresponders. The levels of β2-μ-free HLA class I heavy chains showed only minor changes during and after treatment. We suggest that the determination of hepatitis C virus RNA levels combined with soluble β2-μ-associated HLA class I heavy chains, as a marker of immune activation, could identify interferon-α non responder chronic hepatitis C patients most likely to respond to a retreatment with interferon-α plus ribavirin.

AB - The serum levels of soluble β2-μ-associated and β2-μ-free HLA class I heavy chains were determined in 28 interferon-α nonresponder chronic hepatitis C patients retreated with interferon-α plus ribavirin and in 70 healthy subjects. The baseline levels of β2-μ-associated and β2-μ-free HLA class I heavy chains were significantly higher in patients than in healthy controls (P = 0.001). The levels of β2-μ-associated HLA class I heavy chains significantly increased in responder patients with respect to nonresponders at the third month of treatment (P = 0.03). At the sixth month of treatment and after 6 months of follow up the levels of β2-μ-associated HLA class I heavy chains decreased in responder patients and increased in nonresponders. The levels of β2-μ-free HLA class I heavy chains showed only minor changes during and after treatment. We suggest that the determination of hepatitis C virus RNA levels combined with soluble β2-μ-associated HLA class I heavy chains, as a marker of immune activation, could identify interferon-α non responder chronic hepatitis C patients most likely to respond to a retreatment with interferon-α plus ribavirin.

KW - Chronic hepatitis C

KW - Hepatitis C virus RNA

KW - Interferon-α

KW - Ribavirin

KW - Soluble HLA

UR - http://www.scopus.com/inward/record.url?scp=17744365361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744365361&partnerID=8YFLogxK

U2 - 10.1023/A:1026468001834

DO - 10.1023/A:1026468001834

M3 - Article

VL - 20

SP - 486

EP - 489

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 6

ER -